2069 results about "Virus resistance" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention discloses a bovine I-type alpha interferon-ferritin fusion protein, a mutant thereof, a preparation method and an application of the bovine I-type alpha interferon-ferritin fusion protein. The bovine I-type alpha interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that the expression level, the structural stability and the antiviral activity of the interferon are remarkably improved. The fusion protein is further subjected to single-site or multi-site rational design mutation, and a mutant with significantly improved antiviral activity and stability is obtained. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles have application prospects in preparation of drugs or reagents for preventing or treating bovine viral diseases.

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention belongs to the technical field of genetic engineering, and particularly relates to an antibacterial peptide with antibacterial and antiviral effects and application and a product thereof. The amino acid sequence of the antibacterial peptide provided by the invention has the following general formula: X1GX2FX3FX4KKFX5LFX6X7SKVLK, x1 is M or has no amino acid; x2 is one of R, G and H; x3 is one of KS, KR, HR and HH; x4 is R or L; x5 is one of KK, HH and HK; x6 is RR or KK; and X7 is I or L. The antibacterial peptide disclosed by the invention has a relatively good antibacterial effect, and shows antiviral activity on HPV16 (Human Papilloma Virus 16) and HPV18 (Human Papilloma Virus 18). Good application prospects are shown in the preparation of antibacterial or antiviral products.

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.

The invention discloses a grass carp gamma interferon fusion protein as well as a mutant, a coding gene and application thereof. In order to improve the expression quantity or expression efficiency of the grass carp gamma interferon, codon optimization and mutation are carried out on the coding gene of the grass carp gamma interferon to obtain the grass carp gamma interferon mutant. The fusion protein is further obtained by connecting the grass carp gamma interferon mutant with the C end of the grass carp ferritin heavy chain subunit of which the last 17 amino acids are removed through a connecting peptide. In order to further improve the antiviral activity of the fusion protein, the obtained fusion protein is subjected to single-point mutation, and the titer of the fusion protein is remarkably improved. The fusion protein is expressed by a silkworm cell eukaryotic expression system, and the fusion protein shows a conformation suitable for the interferon to play functions based on the ferritin self-assembly characteristic, so that the titer of the interferon in a host is effectively improved, and the in-vivo and in-vitro half-life period of the interferon is prolonged. The invention has application prospects in preparation of drugs or reagents for preventing or treating viral diseases of grass carp and the like.

The invention relates to the technical field of fermentation of edible and medicinal fungi, and discloses a phellinus igniarius fermentation method capable of producing high-yield Hispidin and an application of the phellinus igniarius fermentation method. The phellinus igniarius fermentation method comprises the following steps: inoculating a phellinus igniarius strain into a culture medium containing a copper ion compound, and fermenting. The phellinus igniarius mycelium obtained by adopting the fermentation method is rich in Hispidin, and can be widely used for preparing related medicines and health foods for protecting liver, resisting tumors, resisting viruses, resisting oxidation, reducing uric acid and the like. In addition, the invention also discloses a high performance liquid chromatography detection method for analyzing the content of Hispidin, by adopting the method, the content of Hispidin and precursor substances (such as protocatechuic acid, protocatechualdehyde, caffeic acid, osmundone and the like) in the phellinus igniarius leavening and derivative products thereof as well as phellinus igniarius mycelia can be effectively analyzed, and the accuracy of Hispidin detection is favorably improved.

The invention discloses application of SlMSBP protein in prevention and treatment of tomato brown fruit wrinkling virus, and belongs to the technical field of plant antiviral gene engineering. The invention researches and verifies that the SlMSBP protein is a tomato protein for regulating and controlling tomato brown crinkled fruit virus infection for the first time. According to the present invention, the expression of the SlMSBP gene in the tomato is inhibited through the virus-induced gene silencing (VIGS) technology, and the accumulation level of the tomato brown crinkled fruit virus in the SlMSBP silencing tomato plant is reduced, such that the SlMSBP has the virus infection promoting function, and the silencing tomato gene SlMSBP has the important effect on the virus infection resistance so as to reduce the harm of the tomato brown crinkled fruit virus on the plant;

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention discloses application of a small molecule compound in prevention and treatment of plant RNA virus infection, and belongs to the technical field of biology. According to the invention, 2 '-amino-2'-deoxyguanosine (ADG) is used as a unique antiviral active component to be applied to prevention and treatment of plant RNA viruses for the first time, and broad-spectrum inhibition of various plant RNA viruses such as turnip mosaic virus (TuMV), tomato mosaic virus (ToMV) and tobacco mosaic virus (TMV) can be realized only by a low concentration of 250 [mu] M and a simple exogenous spraying mode; and after spraying, the normal growth of plants is not influenced, the risk of phytotoxicity is thoroughly avoided, the safety, high efficiency and broad spectrum of plant RNA virus prevention and control are remarkably improved, and important practical application significance is achieved for guaranteeing the yield and quality of crops in agricultural production and promoting agricultural green transformation.

The invention discloses an application of a soybean nucleolus GTP binding protein gene GmNSN1 in soybean resistance to soybean mosaic virus diseases. The invention relates to an application of a soybean nucleolus GTP binding protein gene GmNSN1 as shown in SEQ ID NO.1 and SEQ ID NO.2 in genetic engineering modification of soybean mosaic virus resistance. The soybean nucleolus GTP binding protein gene GmNSN1 can negatively regulate and control the resistance of soybeans to diseased soybean mosaic virus diseases, and the antiviral response of the soybeans can be activated due to function deficiency of the soybean nucleolus GTP binding protein gene GmNSN1. The gene is knocked out through a CRISPR / Cas9 gene editing technology, so that the resistance of soybeans to the soybean mosaic virus disease can be remarkably improved.

The invention relates to a transcription factor OsMYB4P gene and application of the transcription factor OsMYB4P gene in antiviral rice breeding.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention discloses an application of a soybean ARGONAUTE family gene GmAGO5 in soybean resistance to soybean mosaic virus diseases. The invention also discloses application of the soybean ARGONAUTE family gene GmAGO5 as shown in SEQ ID NO.1 and SEQ ID NO.2 in genetic engineering modification of soybean mosaic virus resistance. The soybean ARGONAUTE family gene GmAGO5 can negatively regulate and control the resistance of soybeans to diseased soybean mosaic virus diseases, and the antiviral response of the soybeans can be activated due to function deficiency of the soybean ARGONAUTE family gene GmAGO5. The gene is knocked out through a CRISPR / Cas9 gene editing technology, so that the resistance of soybeans to the soybean mosaic virus disease can be remarkably improved.

The invention provides an additive composition containing a bioactive enzyme and a preparation method of the additive composition, and belongs to the technical field of biological enzymes. The preparation method comprises the following steps: fixing phytic acid and cyclodextrin on hydroxyapatite, modifying with tannic acid, reacting with dithiothreitol modified lysozyme to prepare an immobilized compound, adding 2, 2-dimethoxy-2-phenylacetophenone and methyl methacrylate, and carrying out irradiation reaction with an ultraviolet lamp to prepare the additive composition containing the bioactive enzyme. The broad-spectrum antibacterial property and the antiviral property of the lysozyme are greatly improved, the sterilization effect on gram negative bacteria is obviously improved, meanwhile, the stability of enzyme is greatly improved, the enzyme is not prone to inactivation, the preservation time of the enzyme is prolonged, the application effect of the enzyme is widened, meanwhile, the lysozyme has good killing capacity on oral bacteria and viruses, the addition of preservatives is reduced, and the cost is reduced. The cleaning effect and stability of the product are improved, tooth demineralization can be prevented, decayed teeth can be prevented, and wide application prospects are achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to a pleiotropic protein MEL3 and application thereof. The amino acid sequence of the pleiotropic protein MEL3 or the homologous protein of the pleiotropic protein MEL3 provided by the invention has the following general formula: X1GAX2LX3VLX4GLX5ALISWEKRKRX6, x1 is M or L; the X2 is one of V, SI and AI; x3 is one of K, T, KI and KR; x4 is one of KK, TT, SS and VK; x5 is one of P, K, A and T; and X6 is QQ or is free of amino acid. The pleiotropic protein MEL3 or the homologous protein thereof provided by the invention has broad-spectrum antibacterial activity, can achieve anti-inflammatory and antiviral effects at the same time, and provides a new thought for preparing anti-pathogenic microorganism or anti-inflammatory products.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention discloses a pyridone type coumarin derivative as well as a preparation method and application thereof. The invention autonomously designs and synthesizes a novel pyridone type coumarin derivative. Experimental results show that the pyridone type coumarin derivative has a remarkable inhibition effect on KYSE-70 and KYSE-150 cells, and the pyridone type coumarin derivative has a very good application value in anti-inflammatory, anti-virus, antibacterial or anti-cancer aspects.

The invention discloses a novel isoxazolopyrimidine derivative with anti-new coronavirus activity as well as a preparation method and application of the novel isoxazolopyrimidine derivative. The isoxazolopyrimidine compound provided by the invention has a good inhibition effect on SARS-CoV-2, and relates to the compound shown in the general formula (I), and pharmaceutically acceptable salts and solvent compounds thereof have a good inhibition effect on new coronavirus, and can be used for preparing antiviral drugs related to the new coronavirus for prevention, treatment or adjuvant treatment. # imgabs0 #

The invention relates to a method for inhibiting in-vitro infection of a porcine epidemic diarrhea virus by using JPH203 and application. The JPH203 can be used for preparing an antiviral drug for inhibiting infection of the porcine epidemic diarrhea virus. JPH203 with the concentration of 5 [mu] M is added in the process that Vero cells are infected with PEDV, compared with a control group without JPH203, the virus infection condition, the protein expression quantity, the RNA content and the virus titer of the PEDV in a treatment group with JPH203 are all remarkably reduced, and it is indicated that JPH203 can be used for inhibiting in-vitro infection of the porcine epidemic diarrhea virus.

The invention discloses a bacteriostatic and antiviral bamboo pulp paper-based sanitary isolation bag as well as a preparation method and application thereof, and belongs to the field of functional paper-based packaging materials. The isolation bag takes bamboo pulp fiber paper as a base material, and the surface of the isolation bag is coated with a water-based polyhydroxyalkanoate functional coating. According to the preparation method, a special polyphenol derivative-chitosan quaternary ammonium salt-nano zinc oxide organic-inorganic hybrid factor is introduced, and the problem of agglomeration of nano particles is effectively solved by utilizing the special bridging effect of polyphenol, so that high-density cation capture and oxidation inactivation sites are constructed on the surface of the coating. Compared with the prior art, the method has the advantages that the method does not need to depend on organic fluorine compounds, and the excellent waterproof and oil-proof barrier effect and the efficient inactivation of viruses can be achieved only through the extremely low coating amount. In addition, the isolation bag has unique environmental chemical responsiveness, can be efficiently dissociated under the alkaline condition to facilitate repulping recovery, can be completely biodegraded in the natural environment, and perfectly considers the requirements of biological safety protection and green environmental protection.

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The present invention relates to the field of genetic engineering technology, specifically disclosing a raccoon dog interferon-α and β-defensin fusion protein, its encoding gene, and its application. The raccoon dog interferon-α and β-defensin fusion protein has the amino acid sequence shown in SEQ ID NO:1. The present invention also provides a gene encoding the fusion protein, a recombinant expression vector, and a host cell. The fusion protein provided by the present invention possesses the dual biological activities of raccoon dog interferon-α and β-defensin, and has certain antiviral and antibacterial activities.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention provides a camellia nitidissima plant endophytic bacterium as well as a fungicide and application thereof in resisting influenza A virus. The golden camellia plant endophytic bacteria are bacillus thuringiensis and are preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.32945. A fermentation product of the strain shows good antiviral activity in both in-vitro and in-vivo experiments, and can effectively inhibit replication of influenza viruses and protect infected mice from being damaged by lethal influenza viruses; the compound also shows the effect of regulating immune response, and the secretion of IFN-gamma is enhanced by down-regulating the secretion of proinflammatory factors such as IL-6 and IL-10, so that the immune resistance of the body is improved.

The invention discloses an application of kaempferol in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. The kaempferol can obviously inhibit the replication of the PEDV in Vero and LLC-PK1 cells through 3C-like protease targeting the PEDV, so that the kaempferol can be used for preparing the medicine for preventing and treating the PEDV. Besides, kaempferol, as a natural substance separated from mulberries, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, and does not cause generation of drug-resistant strains and other toxic and side effects after being used for a long time; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

The invention belongs to the technical field of disease prevention and treatment and aquaculture, and relates to application of acacetin in preparation of a medicine for preventing and treating white spot syndrome. The invention discloses that the acacetin has the biological activity of resisting the white spot syndrome virus for the first time, verifies that the acacetin can obviously inhibit the replication of the white spot syndrome virus in the procambarus clarkia body, and simultaneously improves the survival rate of the procambarus clarkia infected by the white spot syndrome virus. The acacetin has a good antiviral effect on the white spot syndrome virus in crustacean aquaculture, and can be applied to prevention and treatment of aquatic animal diseases caused by the white spot syndrome virus.

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

Provided herein are stable formulations containing active ingredients, such as antiviral compositions, or antiretroviral compositions in a powder form for reconstitution for intrarectal delivery to provide pre-exposure prophylaxis (PrEP) against viral infections. The antiviral composition may be tenofovir, for HIV PrEP.